Research programme: antibody therapeutics - Sutro Biopharma

Drug Profile

Research programme: antibody therapeutics - Sutro Biopharma

Alternative Names: anti CD 74 antibody drug conjugates - Sutro Biopharma; DBCO-Alexa647-conjugated SP7219; SP 7219; SP 7675; SP 7676; STRO 001; STRO-002

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sutro Biopharma
  • Class Antibodies; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Folate receptor 1 antagonists; Invariant chain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Dec 2017 Pharmacodynamics data from a preclinical trial in Multiple myeloma and Lymphoma presented at the American Society of Hematology (ASH-2017)
  • 11 Oct 2017 Sutro Biopharma plans a clinical trial for STRO 001 for Multiple myeloma and Lymphoma in first quarter of 2018
  • 22 Jun 2017 Pharmacodynamics data from a preclinical in-vitro study in Cancer presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top